Journal of Multidisciplinary Applied Natural Science
Open Access Journal
Scopus CiteScore 2024
4.8
Calculated on 05 May, 2025
SJR 2024
0.31
Powered by scimagojr.com
Open Access Journal
4.8
Calculated on 05 May, 2025
0.31
Powered by scimagojr.com
https://doi.org/10.47352/jmans.2774-3047.268
Johanna Fransiska Wijaya
Linda Chiuman
Hariyadi Dharmawan Syahputra
Vera Estefania Kaban
Razoki Razoki
Chrismis Novalinda Ginting
Iksen Iksen
Ovarian cancer is a serious disease that affects the ovaries, and its early detection is challenging due to vague symptoms often dismissed as minor ailments. Currently, natural sources have gained attention for their potential role in anticancer treatment. This study aimed to utilize network pharmacology to explore the potential targets and mechanisms of Zanthoxylum acanthopodium in the treatment of ovarian cancer. This study utilized the KNApSAcK and Swiss Target Prediction to identify active compounds and target genes. Additionally, ovarian cancer-specific target genes were sourced from the GEO database. To identify possible key target genes, the network interaction between protein-protein using the STRING database and visualized them in Cytoscape. Subsequent analysis using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enabled us to focus on primary therapeutic targets. Our investigation into Zanthoxylum acanthopodium revealed 10 active compounds that pass Lipinski rule of five and oral bioavailability with acceptable pharmacokinetic profiles, 88 therapeutic targets, and identified 5 hub genes: SRC, CCNB2, MMP9, PTGS2, and PTPRC, which are strongly associated with ovarian cancer progression. Pathway enrichment analysis highlighted several pathways significantly related to the pathogenesis of ovarian cancer. This study elucidates the therapeutic potential and mechanisms of action of Z. acanthopodium as a promising candidate for ovarian cancer treatment. However, further research, including both in vitro and in vivo studies, is necessary to understand its molecular mechanisms comprehensively.
[1] S. M. Penny. (2020). "Ovarian Cancer: An Overview". Radiologic technology. 91 (6): 561-575.
[2] A. S. O'Shea. (2022). "Clinical Staging of Ovarian Cancer". Methods in Molecular Biology. 2424 : 3-10. 10.1007/978-1-0716-1956-8_1.
DOI: https://doi.org/10.1007/978-1-0716-1956-8_1[3] K. K. Gupta, V. K. Gupta, and R. W. Naumann. (2019). "Ovarian cancer: screening and future directions". International Journal of Gynecological Cancer. 29 (1): 195-200. 10.1136/ijgc-2018-000016.
DOI: https://doi.org/10.1136/ijgc-2018-000016[4] V. Tavares, I. S. Marques, I. G. Melo, J. Assis, D. Pereira, and R. Medeiros. (2024). "Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements". International Journal of Molecular Sciences. 25 (3). 10.3390/ijms25031845.
DOI: https://doi.org/10.3390/ijms25031845[5] Y. P. Liu, C. C. Zheng, Y. N. Huang, M. L. He, W. W. Xu, and B. Li. (2021). "Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment". MedComm (2020). 2 (3): 315-340. 10.1002/mco2.55.
DOI: https://doi.org/10.1002/mco2.55[6] A. Naeem, P. Hu, M. Yang, J. Zhang, Y. Liu, W. Zhu, and Q. Zheng. (2022). "Natural Products as Anticancer Agents: Current Status and Future Perspectives". Molecules. 27 (23). 10.3390/molecules27238367.
DOI: https://doi.org/10.3390/molecules27238367[7] A. Adrian, R. A. Syahputra, N. A. Juwita, R. Astyka, and M. F. Lubis. (2023). "Andaliman (Zanthoxylum acanthopodium DC.) a herbal medicine from North Sumatera, Indonesia: Phytochemical and pharmacological review". Heliyon. 9 (5): e16159. 10.1016/j.heliyon.2023.e16159.
DOI: https://doi.org/10.1016/j.heliyon.2023.e16159[8] A. Setiadi, L. U. Karmawan, and Yanti. (2022). "Anti-Arthritic and Anti-Inflammatory Effects of Andaliman Extract and Nanoandaliman in Inflammatory Arthritic Mice". Foods. 11 (22). 10.3390/foods11223576.
DOI: https://doi.org/10.3390/foods11223576[9] J. Yang, X. Song, H. Hu, W. Zhong, R. Cao, Y. Xu, and R. Li. (2022). "Chemical Composition and Antifungal, Anti-Inflammatory, Antiviral, and Larvicidal Activities of the Essential Oils of Zanthoxylum acanthopodium DC. from China and Myanmar". Molecules. 27 (16). 10.3390/molecules27165243.
DOI: https://doi.org/10.3390/molecules27165243[10] T. T. Diep, L. V. Dung, P. V. Trung, N. T. Hoai, D. T. Thao, N. T. T. Uyen, T. T. H. Linh, T. H. N. Ha, and H. T. Truc. (2023). "Chemical Composition, Antimicrobial, Nitric Oxide Inhibition and Cytotoxic Activity of Essential Oils from Zanthoxylum acanthopodium DC. Leaves and Stems from Vietnam". Chemistry & Biodiversity. 20 (8): e202300649. 10.1002/cbdv.202300649.
DOI: https://doi.org/10.1002/cbdv.202300649[11] D. M. Syari, R. Rosidah, P. A. Z. Hasibuan, G. Haro, and D. Satria. (2019). "Evaluation of Cytotoxic Activity Alkaloid Fractions of Zanthoxylum acanthopodium DC. Fruits". Open Access Macedonian Journal of Medical Sciences. 7 (22): 3745-3747. 10.3889/oamjms.2019.495.
DOI: https://doi.org/10.3889/oamjms.2019.495[12] L. Li, L. Yang, L. Yang, C. He, Y. He, L. Chen, Q. Dong, H. Zhang, S. Chen, and P. Li. (2023). "Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine". Chinese Medicine. 18 (1): 146. 10.1186/s13020-023-00853-2.
DOI: https://doi.org/10.1186/s13020-023-00853-2[13] A. L. Hopkins. (2008). "Network pharmacology: the next paradigm in drug discovery". Nature Chemical Biology. 4 (11): 682-90. 10.1038/nchembio.118.
DOI: https://doi.org/10.1038/nchembio.118[14] U. Chandran, N. Mehendale, S. Patil, R. Chaguturu, and B. Patwardhan. (2017). In:" Innovative Approaches in Drug Discovery. 127-164. 10.1016/b978-0-12-801814-9.00005-2.
DOI: https://doi.org/10.1016/B978-0-12-801814-9.00005-2[15] I. Iksen, W. Witayateeraporn, T. Wirojwongchai, C. Suraphan, N. Pornputtapong, N. Singharajkomron, H. M. Nguyen, and V. Pongrakhananon. (2023). "Identifying molecular targets of Aspiletrein-derived steroidal saponins in lung cancer using network pharmacology and molecular docking-based assessments". Scientific Reports. 13 (1): 1545. 10.1038/s41598-023-28821-8.
DOI: https://doi.org/10.1038/s41598-023-28821-8[16] I. Iksen, S. Sinsook, O. Wattanathamsan, K. Buaban, S. Chamni, and V. Pongrakhananon. (2022). "Target Identification of 22-(4-Pyridinecarbonyl) Jorunnamycin A, a Tetrahydroisoquinoline Derivative from the Sponge Xestospongia sp., in Mediating Non-Small-Cell Lung Cancer Cell Apoptosis". Molecules. 27 (24). 10.3390/molecules27248948.
DOI: https://doi.org/10.3390/molecules27248948[17] S. Batool, M. R. Javed, S. Aslam, F. Noor, H. M. F. Javed, R. Seemab, A. Rehman, M. F. Aslam, B. A. Paray, and A. Gulnaz. (2022). "Network Pharmacology and Bioinformatics Approach Reveals the Multi-Target Pharmacological Mechanism of Fumaria indica in the Treatment of Liver Cancer". Pharmaceuticals (Basel). 15 (6). 10.3390/ph15060654.
DOI: https://doi.org/10.3390/ph15060654[18] J. Zhou, H. Li, B. Wu, L. Zhu, Q. Huang, Z. Guo, Q. He, L. Wang, X. Peng, and T. Guo. (2024). "Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer". Scientific Reports. 14 (1): 1860. 10.1038/s41598-024-52413-9.
DOI: https://doi.org/10.1038/s41598-024-52413-9[19] R. Edgar, M. Domrachev, and A. E. Lash. (2002). "Gene Expression Omnibus: NCBI gene expression and hybridization array data repository". Nucleic Acids Research. 30 (1): 207-10. 10.1093/nar/30.1.207.
DOI: https://doi.org/10.1093/nar/30.1.207[20] A. Kawabata, T. Hayashi, Y. Akasu-Nagayoshi, A. Yamada, N. Shimizu, N. Yokota, R. Nakato, K. Shirahige, A. Okamoto, and T. Akiyama. (2022). "CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells". Current Issues in Molecular Biology. 44 (4): 1587-1596. 10.3390/cimb44040108.
DOI: https://doi.org/10.3390/cimb44040108[21] Y. Li, Q. Wang, X. Zheng, B. Xu, W. Hu, J. Zhang, X. Kong, Y. Zhou, T. Huang, and Y. Zhou. (2024). "ScHGSC-IGDC: Identifying genes with differential correlations of high-grade serous ovarian cancer based on single-cell RNA sequencing analysis". Heliyon. 10 (12): e32909. 10.1016/j.heliyon.2024.e32909.
DOI: https://doi.org/10.1016/j.heliyon.2024.e32909[22] A. T. Lun, Y. Chen, and G. K. Smyth. (2016). "It's DE-licious: A Recipe for Differential Expression Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR". Methods in Molecular Biology. 1418 : 391-416. 10.1007/978-1-4939-3578-9_19.
DOI: https://doi.org/10.1007/978-1-4939-3578-9_19[23] Y. Zhang, G. Parmigiani, and W. E. Johnson. (2020). "ComBat-seq: batch effect adjustment for RNA-seq count data". NAR Genomics and Bioinformatics. 2 (3): lqaa078. 10.1093/nargab/lqaa078.
DOI: https://doi.org/10.1093/nargab/lqaa078[24] M. D. Robinson and A. Oshlack. (2010). "A scaling normalization method for differential expression analysis of RNA-seq data". Genome Biology. 11 (3): R25. 10.1186/gb-2010-11-3-r25.
DOI: https://doi.org/10.1186/gb-2010-11-3-r25[25] M. D. Robinson, D. J. McCarthy, and G. K. Smyth. (2010). "edgeR: a Bioconductor package for differential expression analysis of digital gene expression data". Bioinformatics. 26 (1): 139-40. 10.1093/bioinformatics/btp616.
DOI: https://doi.org/10.1093/bioinformatics/btp616[26] F. M. Afendi, T. Okada, M. Yamazaki, A. Hirai-Morita, Y. Nakamura, K. Nakamura, S. Ikeda, H. Takahashi, M. Altaf-Ul-Amin, L. K. Darusman, K. Saito, and S. Kanaya. (2012). "KNApSAcK family databases: integrated metabolite-plant species databases for multifaceted plant research". Plant & Cell Physiology. 53 (2): e1. 10.1093/pcp/pcr165.
DOI: https://doi.org/10.1093/pcp/pcr165[27] A. Daina, O. Michielin, and V. Zoete. (2017). "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules". Scientific Reports. 7 : 42717. 10.1038/srep42717.
DOI: https://doi.org/10.1038/srep42717[28] D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, and V. Zoete. (2014). "SwissTargetPrediction: a web server for target prediction of bioactive small molecules". Nucleic Acids Research. 42 (Web Server issue): W32-8. 10.1093/nar/gku293.
DOI: https://doi.org/10.1093/nar/gku293[29] P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, and T. Ideker. (2003). "Cytoscape: a software environment for integrated models of biomolecular interaction networks". Genome Research. 13 (11): 2498-504. 10.1101/gr.1239303.
DOI: https://doi.org/10.1101/gr.1239303[30] D. Szklarczyk, A. L. Gable, K. C. Nastou, D. Lyon, R. Kirsch, S. Pyysalo, N. T. Doncheva, M. Legeay, T. Fang, P. Bork, L. J. Jensen, and C. von Mering. (2021). "The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets". Nucleic Acids Research. 49 (D1): D605-D612. 10.1093/nar/gkaa1074.
DOI: https://doi.org/10.1093/nar/gkaa1074[31] G. Yu, L. G. Wang, Y. Han, and Q. Y. He. (2012). "clusterProfiler: an R package for comparing biological themes among gene clusters". OMICS. 16 (5): 284-7. 10.1089/omi.2011.0118.
DOI: https://doi.org/10.1089/omi.2011.0118[32] R. Roskoski, Jr. (2023). "Rule of five violations among the FDA-approved small molecule protein kinase inhibitors". Pharmacological Research. 191 : 106774. 10.1016/j.phrs.2023.106774.
DOI: https://doi.org/10.1016/j.phrs.2023.106774[33] A. Caminero Gomes Soares, G. H. Marques Sousa, R. L. Calil, and G. H. Goulart Trossini. (2023). "Absorption matters: A closer look at popular oral bioavailability rules for drug approvals". Molecular Informatics. 42 (11): e202300115. 10.1002/minf.202300115.
DOI: https://doi.org/10.1002/minf.202300115[34] J. R. Wiener, T. C. Windham, V. C. Estrella, N. U. Parikh, P. F. Thall, M. T. Deavers, R. C. Bast, G. B. Mills, and G. E. Gallick. (2003). "Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers". Gynecologic Oncology. 88 (1): 73-9. 10.1006/gyno.2002.6851.
DOI: https://doi.org/10.1006/gyno.2002.6851[35] W. Liu, F. Yue, M. Zheng, A. Merlot, D. H. Bae, M. Huang, D. Lane, P. Jansson, G. Y. Lui, V. Richardson, S. Sahni, D. Kalinowski, Z. Kovacevic, and D. R. Richardson. (2015). "The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1". Oncotarget. 6 (11): 8851-74. 10.18632/oncotarget.3316.
DOI: https://doi.org/10.18632/oncotarget.3316[36] M. J. Li, S. B. Yan, G. Chen, G. S. Li, Y. Yang, T. Wei, D. S. He, Z. Yang, G. Y. Cen, J. Wang, L. Y. Liu, Z. J. Liang, L. Chen, B. T. Yin, R. X. Xu, and Z. G. Huang. (2022). "Upregulation of CCNB2 and Its Perspective Mechanisms in Cerebral Ischemic Stroke and All Subtypes of Lung Cancer: A Comprehensive Study". Frontiers in Integrative Neuroscience. 16 : 854540. 10.3389/fnint.2022.854540.
DOI: https://doi.org/10.3389/fnint.2022.854540[37] I. Iksen, S. Seephan, V. Limprasutr, S. Sinsook, K. Buaban, S. Chamni, and V. Pongrakhananon. (2023). "Preclinical Characterization of 22-(4'-Pyridinecarbonyl) Jorunnamycin A against Lung Cancer Cell Invasion and Angiogenesis via AKT/mTOR Signaling". ACS Pharmacology & Translational Science. 6 (8): 1143-1154. 10.1021/acsptsci.3c00046.
DOI: https://doi.org/10.1021/acsptsci.3c00046[38] C. Liu, Y. Shen, and Q. Tan. (2023). "Diagnostic and prognostic values of MMP-9 expression in ovarian cancer: A study based on bioinformatics analysis and meta-analysis". International Journal of Biological Markers. 38 (1): 15-24. 10.1177/03936155221140421.
DOI: https://doi.org/10.1177/03936155221140421[39] L. W. Cheung, P. C. Leung, and A. S. Wong. (2006). "Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9". Cancer Research. 66 (22): 10902-10. 10.1158/0008-5472.CAN-06-2217.
DOI: https://doi.org/10.1158/0008-5472.CAN-06-2217[40] Z. Y. Tang, Y. Liu, L. X. Liu, X. Y. Ding, H. Zhang, and L. Q. Fang. (2013). "RNAi-mediated MMP-9 silencing inhibits mouse melanoma cell invasion and migration in vitro and in vivo". Cell Biology International. 37 (8): 849-54. 10.1002/cbin.10107.
DOI: https://doi.org/10.1002/cbin.10107[41] L. Deng, D. Q. Feng, and B. Ling. (2020). "Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition". Journal of Zhejiang University: Science B. 21 (4): 315-326. 10.1631/jzus.B1900445.
DOI: https://doi.org/10.1631/jzus.B1900445[42] A. Suri, X. Sheng, K. M. Schuler, Y. Zhong, X. Han, H. M. Jones, P. A. Gehrig, C. Zhou, and V. L. Bae-Jump. (2016). "The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer". Oncotarget. 7 (26): 39582-39594. 10.18632/oncotarget.8659.
DOI: https://doi.org/10.18632/oncotarget.8659[43] X. Li, Z. Yue, D. Wang, and L. Zhou. (2023). "PTPRC functions as a prognosis biomarker in the tumor microenvironment of cutaneous melanoma". Scientific Reports. 13 (1): 20617. 10.1038/s41598-023-46794-6.
DOI: https://doi.org/10.1038/s41598-023-46794-6[44] I. Wertel, D. Suszczyk, A. Pawlowska, M. Bilska, A. Chudzik, W. Skiba, R. Paduch, and J. Kotarski. (2020). "Prognostic and Clinical Value of Interleukin 6 and CD45(+)CD14(+) Inflammatory Cells with PD-L1(+)/PD-L2(+) Expression in Patients with Different Manifestation of Ovarian Cancer". Journal of Immunology Research. 2020 : 1715064. 10.1155/2020/1715064.
DOI: https://doi.org/10.1155/2020/1715064[45] M. Z. Akhter, S. K. Sharawat, V. Kumar, V. Kochat, Z. Equbal, M. Ramakrishnan, U. Kumar, S. Mathur, L. Kumar, and A. Mukhopadhyay. (2018). "Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype". Oncogene. 37 (16): 2089-2103. 10.1038/s41388-017-0106-y.
DOI: https://doi.org/10.1038/s41388-017-0106-y